Treatment of patients with chronic hepatitis C and normal alanine aminotransferase levels with peginterferon alfa-2a (40 KD) (Pegasys®) and ribavirin.

被引：0
|
作者：
Zeuzem, S
Diago-Madrid, M
Shiffman, ML
Reindollar, RW
Pockros, PJ
Gane, E
Tran, A
Farci, P
Lamour, F
机构：
[1] Univ Saarlandes Kliniken, Med Klin & Poliklin, Homburg, Germany
[2] Hosp Gen Valencia, Valencia, Spain
[3] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA
[4] Carolinas Ctr Liver Dis, Charlotte, NC USA
[5] Scripps Clin, La Jolla, CA USA
[6] Middlemore Hosp, Grafton, New Zealand
[7] Hop Archet, Federat Hepatogastroenterol, Nice, France
[8] Univ Cagliari, Dipartiemt Med Sci, Cagliari, Italy
[9] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1680
引用
收藏
页码：583A / 583A
页数：1
相关论文
共 50 条
  • [21] Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Ferenci, P
    Fried, MW
    Shiffman, ML
    Smith, CI
    Marinos, G
    Gonçales, FL
    Häussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxì, A
    Chaneac, M
    Reddy, KR
    JOURNAL OF HEPATOLOGY, 2005, 43 (03) : 425 - 433
  • [22] Hepatic steatosis in chronic hepatitis C: Baseline host and viral characteristics, influence on and response to therapy with peginterferon alfa-2a (40 KD) and ribavirin.
    Reddy, KR
    Govindarajan, S
    Hadziyannis, SJ
    Marcellin, P
    Bernstein, D
    Dienstag, J
    Bodenheimer, H
    Rakela, J
    Messinger, D
    Ackrill, A
    HEPATOLOGY, 2004, 40 (04) : 392A - 392A
  • [23] How normal are normal alanine aminotransferase (ALT) levels in patients with chronic hepatitis C (CHC)?: Data from the randomized, Multinational Peginterferon alfa2a (40KD) (Pegasys®) plus Ribavirin (Copegus®) Trial in patients with persistently 'normal' ALT levels.
    Prati, D
    Shiffman, M
    Diago, M
    Gane, E
    Reddy, K
    Pockros, P
    O'Brien, C
    Lardelli, P
    Lamour, F
    Zeuzem, S
    HEPATOLOGY, 2004, 40 (04) : 395A - 395A
  • [24] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [25] An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC)
    Hornberger, J
    Dusheiko, G
    Lewis, G
    Patel, K
    HEPATOLOGY, 2005, 42 (04) : 653A - 653A
  • [26] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [27] Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).
    Ferenci, P
    Shiffman, ML
    Fried, MW
    Sulkowski, MS
    Haeussinger, D
    Zarski, JP
    Goncales, F
    Jensen, DM
    Bonino, F
    Dhumeaux, D
    Blotner, S
    Hoffman, J
    Oliveto, J
    HEPATOLOGY, 2001, 34 (04) : 351A - 351A
  • [28] Treatment of patients with chronic hepatitis C with peginterferon alfa-2a (40KD) (Pegasys®) alone or in combination with ribavirin results in long-lasting sustained virological response.
    Swain, M
    Lai, MY
    Shiffmann, ML
    Cooksley, WGE
    Abergel, A
    Diago, M
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 598A - 598A
  • [29] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [30] Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C
    van Leusen, Robert
    Adang, Rob P. R.
    de Vries, Richard A.
    Cnossen, Trijntje T.
    Konings, Constantijn J. A. M.
    Schalm, Solko W.
    Tan, Adriaan C. I. T. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (02) : 721 - 725
12345